With a simple blood draw, the Guardant360 test is helping to guide treatment decisions for advanced lung cancer patients. In this patient case, the Guardant360 test detected BRAF V600E, a targetable alteration that was not detected by hotspot testing in a 77-year-old lung cancer patient. Treated with the right precision medicine, dabrafenib, combined with trametinib, the patient responded well to treatment. This is an actual patient case, but the image and name are not real to maintain patient’s confidentiality. 
 
Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at [email protected] or contact us on WhatsApp: +65 8940 0360. 
 
Guardant360®. Test. Take Action.